ChemoCentryx to Present at the 32nd Annual J.P. Morgan Healthcare Conference

MOUNTAIN VIEW, Calif., Jan. 8, 2014 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI), today announced that Thomas J. Schall, Ph.D., President and Chief Executive Officer, will present at the 32nd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2014, at 3:30 p.m. Pacific Time. The conference will be held at the Westin St. Francis Hotel in San Francisco, CA.

A live audio webcast of the presentation can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. A replay of the webcast will be available on the Company's website for two weeks following the presentation.

About ChemoCentryx

ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. CCX168, a C5aR inhibitor, has recently completed the first two steps in an ongoing Phase II trial for the treatment of anti-neutrophil cytoplasmic antibody-associated renal vasculitis (AARV). CCX168 appears to be safe, well tolerated and successful in allowing both reduction and elimination of high-dose corticosteroids, part of standard of care for AARV patients, without compromising efficacy or safety during a 12-week treatment period. Vercirnon (also known as Traficet-EN or CCX282) is a specific CCR9 inhibitor for the treatment of inflammatory bowel disease. Other clinical programs include CCX872, a next generation CCR2 inhibitor, and CCX507, a next generation CCR9 inhibitor, both of which are in Phase I clinical testing and CCX354, a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis. ChemoCentryx also has several programs in advanced preclinical development.

Source: ChemoCentryx, Inc.

CCXI-G

CONTACT: Susan M. Kanaya
         Senior Vice President, Finance and
         Chief Financial Officer
         Or

         Markus J. Cappel, Ph.D.
         Chief Business Officer
         650-210-2900
         [email protected]

         Media:
         Susan Kinkead
         Kinkead Communications
         [email protected]
         415-751-3611

         Investors:
         Caitlyn Murphy
         Burns McClellan
         [email protected]
         212-213-0006

You May Also Be Interested In

• JPMorgan Starts Auna SA (AUNA) at Overweight, 'Buying LatAm Healthcare Growth at Discounted Terms'
• Thumzup® to Host Culver City's Chamber of Commerce Networking Event
• Health Advocate Partners with Tava Health to Expand Access to Virtual Therapy